Braze Inc
Change company Symbol lookup
Select an option...
BRZE Braze Inc
MGF MFS? Government Markets Income
LI Li Auto Inc
APAC Stonebridge Acquisition Corp
KAJMF Kajima Corp
TALKW Talkspace Equity Warrant Exp 21 June 2025 *W EXP 06/21/2025
GCTK GlucoTrack Inc
SIVBP SVB Financial Group
CYBR Cyberark Software Ltd
DD Dupont De Nemours Inc
Go

Company profile

Braze, Inc. is a provider of customer engagement platform that enables customer-centric interactions between consumers and brands. Its platform helps brands to listen to their customers, understand them and act on that understanding in a way that is human and personal. Using the Company’s platform, brands ingest and process customer data in real time, orchestrate and optimize contextually relevant, cross-channel marketing campaigns and continuously evolve their customer engagement strategies. Its platform enables interactions with active users via its customers’ applications, Websites and other digital interfaces. Its platform encompasses the functionalities required for modern customer engagement, which include data ingestion, classification, orchestration, personalization, and action. The Company offers software development kits (SDKs) for installation into customers’ applications on platforms such as Android, iPhone Operating System (iOS) and desktop / mobile Web.

Closing Price
$39.00
Day's Change
-0.45 (-1.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
40.39
Day's Low
38.90
Volume
(Average)
Volume:
497,921

10-day average volume:
525,607
497,921

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

8:00 am ET July 12, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:MXCT),(LSE:MXCT),(LSE:MXCN), EQNX::TICKER_END MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

Under the terms of the agreement, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Further accelerating its efforts for clinical development of global new drugs, LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeutic.

Doug Doerfler, President and CEO of MaxCyte, said: "We are thrilled to partner with the global multinational company LG Chem to support their CAR T programs for solid tumors. This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer."

MaxCyte's ExPERT(TM) instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT(TM) platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. LG CHEM is MaxCyte's first SPL in Asia and 17th overall, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx(TM), STx(TM) and GTx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser                                +1 415-937-5400
Gilmartin Group                              ir@maxcyte.com
David Deuchler, CFA
US Media Relations                           +1 408-497-8568
Valerie Enes                                 valerie@teamseismic.com
Seismic
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser                                +44 (0)203 709 5700
Consilium Strategic Communications           maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

comtex tracking

COMTEX_410027027/2010/2022-07-12T08:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.